Blog

10 Million Reasons I'm Not Selling Fulgent Genetics

A once-a-century pandemic has created a tough task for management teams trying to forecast the future. A wave of COVID-19 can shut down businesses, ramp up online commerce, and generally upend any

TheMotleyFool

0

Here's How You Handle a Volatile Stock Like Cassava Sciences

When I first noticed Cassava Sciences (NASDAQ: SAVA) in July, the stock had already gone up by more than 1,000% over six months, from $7 per share to $90. What does that dramatic price shift say to

TheMotleyFool

0

How Does Square Make Its Money?

Fintech giant Square (NYSE: SQ) has several different ways it generates revenue, and many investors don't really understand how much comes from each source. In this Fool Live video clip, recorded on

TheMotleyFool

0

Down More Than 60%, This Stock Could Be a Steal

Longtime Fool.com contributors Matt Frankel, CFP, and Jason Hall compared some of their portfolios' most beaten-down stocks on an episode of The Rank, recorded on Aug. 23. The worst performer in

TheMotleyFool

0

Is Exelixis Stock a Buy?

Biotech specialist Exelixis (NASDAQ: EXEL) has had a rough year in the stock market. On June 28, the company's shares dropped by more than 20% on the heels of unimpressive results from a clinical

TheMotleyFool

0

Buying Cybin Stock Right Now Could Be a Brilliant Move

As the proverb goes, talent hits targets that nobody else can hit, but genius hits targets that nobody else can see. If you want your portfolio to outperform, sometimes it's necessary to look for

TheMotleyFool

0

These 2 Unstoppable Stocks Just Got a Shot in the Arm

To say that Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) investors have had a great year would be an understatement. The two stocks have gained around 265% and 340%, respectively, year to

TheMotleyFool

0

Is Pfizer a Buy?

Most of the headlines over the past two years about Pfizer (NYSE: PFE) have involved its vaccine for COVID-19. That makes sense. We have been in the middle of a pandemic. But the picture is clearing

TheMotleyFool

0

Axonics: Buy at the High?

Axonics (NASDAQ: AXNX) specializes in making medical devices to treat bladder and bowel dysfunction. It's the type of therapy that may be embarrassing to some, but the company's financial

TheMotleyFool

0

Will Roku Achieve a Trillion-Dollar Market Cap by 2030?

After the reaction to its recent second-quarter earnings report, a $1 trillion market cap is probably the last thing on the minds of Roku (NASDAQ: ROKU) investors. The stock began to drop after the

TheMotleyFool

0

3 Pot Stocks to Avoid Like the Plague in September

There's a very good chance that legal cannabis could be one of the decade's most impressive growth trends.

According to New Frontier Data, the U.S. weed market is on track to grow by an annualized

TheMotleyFool

0

3 Biotech Stocks That Are Too Cheap to Ignore

There are plenty of biotech stocks that are expensive. Their valuations depend on highly risky pipeline candidates achieving success. But not every biotech stock is priced at a premium.

We asked

TheMotleyFool

0

2 Stocks to Buy with Dividends Yielding More than 6%

If youʻre an income investor, you want a stock with a strong dividend yield -- that is, the amount of its cash payouts as a percentage of its share price. The average dividend yield is south of 2%

TheMotleyFool

0

Now May Be the Big Moment for These 2 COVID Stocks

When most of us think of successful coronavirus stocks, we think of vaccine makers. But treatment makers are gaining momentum these days -- and that movement may not be over. Why? Coronavirus cases

TheMotleyFool

0

3 Top Mid-Cap Stocks to Buy in September

Some stocks might seem too big to generate explosive growth. Others could be so small that their risk level isn't appealing. However, similar to the old story of Goldilocks and the three bears

TheMotleyFool

0

3 Growth Stocks That'll Make You Richer in September (and Beyond)

For the past 12 years, growth stocks have rightly been the talk of Wall Street. Precipitously declining interest rates and abundant access to cheap capital have allowed fast-paced companies to

TheMotleyFool

0

Want a $1 Million Nest Egg? Here's the Monthly Retirement Plan Contribution That Could Pull It Off

Many people dream of retiring with $1 million or more to their name. Now the reality is that you don't really have to fixate on a $1 million nest egg. You may be able to do just fine in retirement

TheMotleyFool

0

Social Security Benefit Cuts Could Happen by 2034, Trustees Say

Each year, the Social Security Trustees release a report outlining the state of the program's finances. This year's report was delayed by many months, but it was finally released at the end of

TheMotleyFool

0